A new probe developed uses an innovative fluorescence-reading technology to help brain surgeons distinguish cancerous tissue from normal tissue. The probe tool, now already in use at the Cancer Center for brain surgery, may one day be used for surgeries for a variety of cancers.
Doctors performed the first-ever FDA approved Schwann cell transplantation in a patient with a new spinal cord injury. The procedure is a Phase 1 clinical trial designed to evaluate the safety and feasibility of transplanting the patient’s own Schwann cells.
Neurosurgeons have developed a new way to perform deep brain stimulation surgeries. The new technique allows for more accurate placement of the electrodes in the brain and is likely to be safer for patients.